Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.
1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.
Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.
Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.
From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.
The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.
November 16, 2023 - In-Person in Munich
October 27, 2023
October 3 and 5, 2023
Daniel (Dan) J. Pereira, Ph.D., is the firm's Managing Partner, Co-Head of the Chemical Practice Group and member of the management committee. His practice focuses on client counseling, portfolio management, patent prosecution, litigation and interferences involving a wide range of technologies including battery materials (including solid electrolytes, solid-state batteries, and anode and cathode materials for lithium-ion batteries), recombinant DNA technology, genetics, immunology, enzymology, medical diagnostics, bioinformatics, microarrays, statistical data analysis, genomics, proteomics, nanotechnology, polymer chemistry, metallurgy, solar technology, imaging, medical devices, optical films, coatings, cosmetics, catalysts, ceramics, alloys, chemical engineering, optical and electronic devices. Dr. Pereira has particular expertise in the medical, biotechnology, and pharmaceutical fields.
Dr. Pereira has served as co-counsel on interferences cases, advising on issues ranging from strategies for avoiding interferences to strategies for provoking them. He has also acted as co-counsel in declared interferences. Dr. Pereira handles appeals before the Patent Trial and Appeal Board (PTAB), district court patent litigations, and Federal Circuit appeals, and has extensive experience providing pre-litigation and litigation avoidance counseling to clients. Additionally, Dr. Pereira assists both foreign and domestic clients of all sizes with licensing and contract negotiations, due diligence analyses and risk assessment in intellectual property asset acquisition transactions.
Prior to joining the firm, Dr. Pereira worked as a post-doctoral research scientist at the Mount Sinai School of Medicine where he conducted research in the fields of neurodegeneration and transgenic mouse models of human disease. While obtaining his degrees, he studied gene expression and gene therapy and performed research in the area of leukemia pathogenesis.